drugset / Trial / NCT05238454
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01C in Population Aged ≥18 Years and Previously Fully Vaccinated With COVID-19 Vaccine
RandomizedParallel-groupTriple-blindPrevention
Summary
The objective of this study is to evaluate the immunogenicity and safety of SCTV01C in participants aged ≥18 years and previously fully immunized with either inactivated or mRNA COVID-19 vaccine or previously diagnosed with COVID-19.
Timeline
- Start
- 2022-03-20
- Primary completion
- 2022-07-01
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BNT162b2 | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | SCTV01C | Vaccine | — | Intramuscular |
| Comparator | Sinopharm inactivated COVID-19 vaccine | Vaccine | — | Intramuscular |